Annovis Bio to Launch Open-Label Extension Study for Parkinson's Therapy Buntanetap in 2026

Annovis Bio Inc. (NYSE: ANVS) announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson disease. The study will provide continued access to buntanetap for participants from prior clinical trials while enabling extended monitoring of safety outcomes, sustained effects on motor and cognitive function, and the collection of biomarker data to support further evaluation of buntanetap's potential as a disease-modifying therapy for neurodegenerative disorders.

This extension study represents a significant step in the clinical development pathway for buntanetap, allowing researchers to gather valuable long-term data that could demonstrate sustained benefits for Parkinson's disease patients. By continuing treatment for participants from previous trials, the study addresses ethical considerations around access to investigational therapies while simultaneously advancing scientific understanding of buntanetap's effects over extended periods. The collection of biomarker data is particularly important as it may provide objective evidence of the therapy's impact on disease progression, which is crucial for establishing disease-modifying properties.

The announcement comes at a time when the neurodegenerative disease treatment landscape is evolving rapidly, with increasing focus on therapies that can modify disease course rather than merely managing symptoms. Parkinson's disease affects millions worldwide, and current treatments primarily address symptoms without altering the underlying disease progression. The extension study's design allows for comprehensive assessment of both motor and cognitive functions, addressing two key domains of impairment in Parkinson's disease that significantly impact patients' quality of life.

For more information about the company, visit https://www.AnnovisBio.com. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. This development in Parkinson's disease research represents an important advancement in the field of neurodegenerative disorder therapeutics, with potential implications for treatment approaches across multiple conditions characterized by protein aggregation and neuronal dysfunction.